Identification of novel vaccine candidates for Chagas’ disease by immunization with sequential fractions of a trypomastigote cDNA expression library

Tekiel, Valeria; Soto, Catalina Dirney Alba; Cappa, S. M. González; Postan, Miriam; Sánchez, Daniel O.

doi:10.1016/j.vaccine.2008.12.056

Cited by 29 publications

(37 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Confirming this theory, in vitro screening of both B-and T-cell epitopes identified ASFV determinants that, however, failed to induce any measurable protection (61,62). This is most probably the main reason why there are only a few reports identifying optimal vaccine candidates screened from successful ELI libraries obtained from large and complex pathogens (63). The fact that we are working with a real infection model allows for optimism.…”

Section: Fig 4 Kinetics Of the Detection Of Ifn-␣ (A) And Tnf-␣ (B) Imentioning

confidence: 66%

Expression Library Immunization Can Confer Protection against Lethal Challenge with African Swine Fever Virus

Lacasta

Ballester

Monteagudo

et al. 2014

J Virol

110

112

View full text Add to dashboard Cite

African swine fever is one of the most devastating pig diseases, against which there is no vaccine available. Recent work from our laboratory has demonstrated the protective potential of DNA vaccines encoding three African swine fever viral antigens (p54, p30, and the hemagglutinin extracellular domain) fused to ubiquitin. Partial protection was afforded in the absence of detectable antibodies prior to virus challenge, and survival correlated with the presence of a large number of hemagglutinin-specific CD8 IMPORTANCEAfrican swine fever is a highly contagious disease of domestic and wild pigs that is endemic in many sub-Saharan countries, where it causes important economic losses and is currently in continuous expansion across Europe. Unfortunately, there is no treatment nor an available vaccine. Early attempts using attenuated vaccines demonstrated their potential to protect pigs against experimental infection. However, their use in the field remains controversial due to safety issues. Although inactive and subunit vaccines did not confer solid protection against experimental ASFV infection, our DNA vaccination results have generated new expectations, confirming the key role of T-cell responses in protection and the existence of multiple ASFV antigens with protective potential, more of which are currently being identified. Thus, the future might bring complex and safe formulations containing more than a single viral determinant to obtain broadly protective vaccines. We believe that obtaining the optimal vaccine formulation it is just a matter of time, investment, and willingness.

show abstract

Section: Fig 4 Kinetics Of the Detection Of Ifn-␣ (A) And Tnf-␣ (B) Imentioning

confidence: 66%

Expression Library Immunization Can Confer Protection against Lethal Challenge with African Swine Fever Virus

Lacasta

Ballester

Monteagudo

et al. 2014

J Virol

110

112

View full text Add to dashboard Cite

show abstract

“…52,53 Alternatively, immunization with a trypomastigote cDNA library and the sequential selection of protective pools has also been used to identify a series of novel antigens able to confer increased survival following infectious challenge. 54 Similarly, a novel family of surface proteins has been recently identified that seems to be specific for T. cruzi. 55 Taken together, these studies may thus lead to some promising antigens with important potential as novel vaccine candidates.…”

Section: ©2 0 1 1 L a N D E S B I O S C I E N C E D O N O T D I S Tmentioning

confidence: 99%

Advances and challenges towards a vaccine against Chagas disease

Quijano-Hernández

Dumonteil

2011

Human Vaccines

View full text Add to dashboard Cite

“…Like other neglected diseases, it is a major health problem resulting from inadequate therapy and the lack of an effective vaccine [2,3]. Treatment of Chagas disease requires long-term dosage regimes with nifurtimox (Nfx; Lampit, Bayer Healthcare, Leverkusen) or benznidazole (Bnz; LAFEPE, Pernambuco), however, severe side effects often prompt the discontinuation of the treatment [4].…”

Section: Introductionmentioning

confidence: 99%

3-H-[1,2]Dithiole as a New Anti-Trypanosoma cruzi Chemotype: Biological and Mechanism of Action Studies

et al. 2015

View full text Add to dashboard Cite

Abstract:The current pharmacological Chagas disease treatments, using Nifurtimox or Benznidazole, show limited therapeutic results and are associated with potential side effects, OPEN ACCESSMolecules 2015, 20 14596 like mutagenicity. Using random screening we have identified new chemotypes that were able to inhibit relevant targets of the Trypanosoma cruzi. We found 3H-[1,2]dithioles with the ability to inhibit Trypanosoma cruzi triosephosphate isomerase (TcTIM). Herein, we studied the structural modifications of this chemotype to analyze the influence of volume, lipophilicity and electronic properties in the anti-T. cruzi activity. Their selectivity to parasites vs. mammalian cells was also examined. To get insights into a possible mechanism of action, the inhibition of the enzymatic activity of TcTIM and cruzipain, using the isolated enzymes, and the inhibition of membrane sterol biosynthesis and excreted metabolites, using the whole parasite, were achieved. We found that this structural framework is interesting for the generation of innovative drugs for the treatment of Chagas disease.

show abstract

Identification of novel vaccine candidates for Chagas’ disease by immunization with sequential fractions of a trypomastigote cDNA expression library

Cited by 29 publications

References 50 publications

Expression Library Immunization Can Confer Protection against Lethal Challenge with African Swine Fever Virus

Expression Library Immunization Can Confer Protection against Lethal Challenge with African Swine Fever Virus

Advances and challenges towards a vaccine against Chagas disease

3-H-[1,2]Dithiole as a New Anti-Trypanosoma cruzi Chemotype: Biological and Mechanism of Action Studies

Contact Info

Product

Resources

About